Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CK-1827452 · 3 trials · 3 indications
Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.
Time of observed maximum plasma concentration (T max) measured in hours (hr) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.
Area under the curve (AUC) measured in hours \* nanograms per milliliter (hr\*ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.
Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).
Time of observed maximum plasma concentration (T max) measured in hours (hr) post dose on day 10. Only one dose was administered on day 10 (final dose of study).
Area under the curve (AUC) measured in hours \* nanograms per milliliter (hr\*ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.
Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.
Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: MR 50 mg BID | EXPERIMENTAL | Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days. |
| Cohort 2: IR 37.5 mg TID | EXPERIMENTAL | Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days. |
| Cohort 3: MR 100 mg BID | EXPERIMENTAL | Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days |
| Mid Dose CK-1827452 or Placebo | EXPERIMENTAL | CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose |
| High Dose CK-1827452 or Placebo | EXPERIMENTAL | CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose |
| Cohort 1 | EXPERIMENTAL | 4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart. |
| Cohort 2 | EXPERIMENTAL | 4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart. |
| Cohort 3 | EXPERIMENTAL | 4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart. |
| Cohort 4 | EXPERIMENTAL | 4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart. |
| Cohort 5 | EXPERIMENTAL | 2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1. |
| Name | Type | Description |
|---|---|---|
| CK-1827452 | DRUG | 50 mg MR CK-1827452 BID for 10 days |
| CK-1827452 24mg and 6 mg iv infusion | DRUG | I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr |
| CK-1827452 12.5mg capsule | DRUG | 12.5mg oral immediate release capsule |
| CK-1827452 48 mg and 11 mg iv infusion | DRUG | I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr |
| CK-1827452 25mg capsule | DRUG | 25mg oral immediate release capsule |
| Placebo iv infusion | DRUG | Matching placebo iv infusion |
| Placebo capsule | DRUG | Matching placebo oral immediate release capsule |
| Placebo | DRUG | IV infusion for 2 hours |
Inclusion Criteria: 1. The patient has signed an Informed Consent Form/Patient Information Sheet for this study approved by the governing Institutional Review Board (IRB) or Independent Ethics Committee (IEC) 2. The patient is at least 18 years old at the time of consent 3. Left ventricular ejectio...
Top 20 of 31 competitors
CK-1827452 is an investigational small molecule being developed for the treatment of heart failure. It is a cardiovascular therapeutic that has been studied in patients with stable heart failure, as well as in those with ischemic cardiomyopathy and angina. The drug is currently in Phase 2 clinical development.
CK-1827452 is being developed by Cytokinetics, Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CYTK. The company has conducted Phase 2 clinical trials to evaluate the drug's safety, tolerability, and pharmacokinetics in patients with heart failure.
CK-1827452 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Three Phase 2 trials have been completed, all of which were randomized, double-blind, and controlled, with a total enrollment of 174 patients.
CK-1827452 has been studied in three completed Phase 2 clinical trials: NCT00624442, a study of CK-1827452 infusion in stable heart failure with 45 patients; NCT00682565, a pharmacokinetic and tolerability study in patients with ischemic cardiomyopathy and angina with 94 patients; and NCT00941681, a pharmacokinetic study of oral CK-1827452 in stable heart failure with 35 patients.
CK-1827452 is also known as omecamtiv mecarbil. It is a cardiac myosin activator being developed by Cytokinetics for heart failure. The drug has been evaluated in Phase 2 trials for its effects on cardiac function and pharmacokinetics in patients with heart failure and related conditions.